Colorectal News and Research

RSS

USPTO issues three patents to Rosetta Genomics

Rosetta Genomics today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs.

4 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

Study finds racial, ethnic and socioeconomic disparities in cancer incidence

A New Jersey study found that African-Americans with cancer are less likely to survive it than whites, and residents of poor neighborhoods less likely to survive than are those in wealthier areas of the state.

3 Feb 2010

Loyola surgeon performs complicated laparoscopic procedure

Mild cases of diverticulitis can be treated with changes in diet, rest and antibiotics. However, Bunch's condition was more serious and the chances of recurrences were high. Her doctors at Loyola University Health System said her best option would be surgery to remove the inflamed section of colon.

2 Feb 2010

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient?

From QIAGEN Manchester Limited 29 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

GI practices team up with NeuIsys to bring advanced imaging technologies for patients

NeuIsys Imaging System Solutions, LLC, a leader in providing state-of-the-art CT and MR imaging systems to physician practices, announced today that three gastroenterology (GI) practices have entered into agreements with NeuIsys to plan, install, and service the recently FDA approved NeuViz 16 Multi-Slice Computed Tomography (CT) System.

28 Jan 2010

CT colonography remains an effective colorectal cancer screening tool for older individual

Computed tomographic colonography (CTC), also known as virtual colonoscopy, remains effective in screening older patients for colorectal cancer (CRC), produces low referral for colonoscopy rates similar to other screening exams now covered by Medicare, and does not result in unreasonable levels of additional testing resulting from extracolonic findings, according to a study published in the February issue of Radiology.

27 Jan 2010

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has met with the FDA regarding it’s supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for injection for the treatment of patients with advanced metastatic colorectal cancer. In October 2009, the FDA issued a Complete Response letter regarding its sNDA for FUSILEV.

25 Jan 2010

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.

24 Jan 2010

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients.

24 Jan 2010

HealthPartners Medical Group to provide timely colorectal cancer screening for African American patients

HealthPartners Medical Group today announced that it has launched an initiative aimed at saving lives by providing more timely colorectal cancer screening for African American patients.

22 Jan 2010

Association between vitamin D and risk of colorectal cancer identified

High blood levels of vitamin D are associated with a lower risk of colon cancer, finds a large European study published on bmj.com today. The risk was cut by as much as 40% in people with the highest levels compared with those in the lowest.

22 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

Leafy green vegetables, folate and multivitamins can prevent lung cancer in smokers

Leafy green vegetables, folate, and some multivitamins could serve as protective factors against lung cancer in current and former smokers, according to a study that is a first step in understanding a complex association.

19 Jan 2010

Surveillance colonoscopy need to be better aligned with patients' risks for colorectal cancer

How often patients receive surveillance colonoscopy may need to be better aligned with their risks for colorectal cancer, according to two papers published this month by University of Pittsburgh School of Medicine researchers.

18 Jan 2010

Treatment for metastatic tumor based on its unique protein makeup

Imagine if treatments for disease could be based not on a patient's diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.

18 Jan 2010

Study results show increase of mortality due to colon cancer in Spain

There are stark geographical contrasts in the incidence of colon cancer worldwide. The new study analyses the causes of these disparities, starting with Spanish trends between 1951 and 2006 in terms of certain changes in consumption (tobacco, alcohol, red and processed meat, fish, vegetables...) and also behaviour (physical exercise, sedentary lifestyles-).

18 Jan 2010

Colorectal News and Research

USPTO issues three patents to Rosetta Genomics

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Study finds racial, ethnic and socioeconomic disparities in cancer incidence

Loyola surgeon performs complicated laparoscopic procedure

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

Celgene reports total revenue of $758M for fourth-quarter of 2009

GI practices team up with NeuIsys to bring advanced imaging technologies for patients

CT colonography remains an effective colorectal cancer screening tool for older individual

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

HealthPartners Medical Group to provide timely colorectal cancer screening for African American patients

Association between vitamin D and risk of colorectal cancer identified

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Fc engineering enhances antibody half-life

Leafy green vegetables, folate and multivitamins can prevent lung cancer in smokers

Surveillance colonoscopy need to be better aligned with patients' risks for colorectal cancer

Treatment for metastatic tumor based on its unique protein makeup

Study results show increase of mortality due to colon cancer in Spain

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News